205 related articles for article (PubMed ID: 23441963)
1. A randomized, double-blind, parallel-group, placebo-controlled trial of Extract Sceletium tortuosum (Zembrin) in healthy adults.
Nell H; Siebert M; Chellan P; Gericke N
J Altern Complement Med; 2013 Nov; 19(11):898-904. PubMed ID: 23441963
[TBL] [Abstract][Full Text] [Related]
2. Electropharmacogram of Sceletium tortuosum extract based on spectral local field power in conscious freely moving rats.
Dimpfel W; Schombert L; Gericke N
J Ethnopharmacol; 2016 Jan; 177():140-7. PubMed ID: 26608705
[TBL] [Abstract][Full Text] [Related]
3. Sceletium tortuosum (Zembrin
Reay J; Wetherell MA; Morton E; Lillis J; Badmaev V
Hum Psychopharmacol; 2020 Nov; 35(6):1-7. PubMed ID: 32761980
[TBL] [Abstract][Full Text] [Related]
4. An acute dose-ranging evaluation of the antidepressant properties of Sceletium tortuosum (Zembrin®) versus escitalopram in the Flinders Sensitive Line rat.
Gericke J; Lekhooa M; Steyn SF; Viljoen AM; Harvey BH
J Ethnopharmacol; 2022 Feb; 284():114550. PubMed ID: 34454055
[TBL] [Abstract][Full Text] [Related]
5. Proof-of-Concept Randomized Controlled Study of Cognition Effects of the Proprietary Extract Sceletium tortuosum (Zembrin) Targeting Phosphodiesterase-4 in Cognitively Healthy Subjects: Implications for Alzheimer's Dementia.
Chiu S; Gericke N; Farina-Woodbury M; Badmaev V; Raheb H; Terpstra K; Antongiorgi J; Bureau Y; Cernovsky Z; Hou J; Sanchez V; Williams M; Copen J; Husni M; Goble L
Evid Based Complement Alternat Med; 2014; 2014():682014. PubMed ID: 25389443
[TBL] [Abstract][Full Text] [Related]
6. Sceletium tortuosum: A review on its phytochemistry, pharmacokinetics, biological and clinical activities.
Olatunji TL; Siebert F; Adetunji AE; Harvey BH; Gericke J; Hamman JH; Van der Kooy F
J Ethnopharmacol; 2021 Nov; 280():114476. PubMed ID: 34333104
[TBL] [Abstract][Full Text] [Related]
7. A toxicological safety assessment of a standardized extract of Sceletium tortuosum (Zembrin®) in rats.
Murbach TS; Hirka G; Szakonyiné IP; Gericke N; Endres JR
Food Chem Toxicol; 2014 Dec; 74():190-9. PubMed ID: 25301237
[TBL] [Abstract][Full Text] [Related]
8. Effect of Zembrin
Dimpfel W; Franklin R; Gericke N; Schombert L
J Ethnopharmacol; 2018 Sep; 223():135-141. PubMed ID: 29758341
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of orally administered extract of red vine leaf AS 195 (folia vitis viniferae) in chronic venous insufficiency (stages I-II). A randomized, double-blind, placebo-controlled trial.
Kiesewetter H; Koscielny J; Kalus U; Vix JM; Peil H; Petrini O; van Toor BS; de Mey C
Arzneimittelforschung; 2000 Feb; 50(2):109-17. PubMed ID: 10719612
[TBL] [Abstract][Full Text] [Related]
10. Sceletium tortuosum: A review on its phytochemistry, pharmacokinetics, biological, pre-clinical and clinical activities.
Olatunji TL; Siebert F; Adetunji AE; Harvey BH; Gericke J; Hamman JH; Van der Kooy F
J Ethnopharmacol; 2022 Apr; 287():114711. PubMed ID: 34758918
[TBL] [Abstract][Full Text] [Related]
11. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
Kisicki JC; Fiske K; Lyne A
Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers.
Davis J; Hackman F; Ndongo MN; Choo H; Lewis D; Tawadrous M; Goodrich J; Langdon G
Clin Ther; 2010 Oct; 32(11):1889-95. PubMed ID: 21095483
[TBL] [Abstract][Full Text] [Related]
13. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
Vaughan D; Speed J; Medve R; Andrews JS
Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
[TBL] [Abstract][Full Text] [Related]
14. Acute effects of Sceletium tortuosum (Zembrin), a dual 5-HT reuptake and PDE4 inhibitor, in the human amygdala and its connection to the hypothalamus.
Terburg D; Syal S; Rosenberger LA; Heany S; Phillips N; Gericke N; Stein DJ; van Honk J
Neuropsychopharmacology; 2013 Dec; 38(13):2708-16. PubMed ID: 23903032
[TBL] [Abstract][Full Text] [Related]
15. The effects of Sceletium tortuosum (L.) N.E. Br. extract fraction in the chick anxiety-depression model.
Carpenter JM; Jourdan MK; Fountain EM; Ali Z; Abe N; Khan IA; Sufka KJ
J Ethnopharmacol; 2016 Dec; 193():329-332. PubMed ID: 27553978
[TBL] [Abstract][Full Text] [Related]
16. A Chewable Cure "Kanna": Biological and Pharmaceutical Properties of
Manganyi MC; Bezuidenhout CC; Regnier T; Ateba CN
Molecules; 2021 Apr; 26(9):. PubMed ID: 33924742
[No Abstract] [Full Text] [Related]
17. A novel approach in herbal quality control using hyperspectral imaging: discriminating between Sceletium tortuosum and Sceletium crassicaule.
Shikanga EA; Viljoen AM; Vermaak I; Combrinck S
Phytochem Anal; 2013; 24(6):550-5. PubMed ID: 23592330
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
[TBL] [Abstract][Full Text] [Related]
19. Modulation of glucocorticoid, mineralocorticoid and androgen production in H295 cells by Trimesemine™, a mesembrine-rich Sceletium extract.
Swart AC; Smith C
J Ethnopharmacol; 2016 Jan; 177():35-45. PubMed ID: 26608706
[TBL] [Abstract][Full Text] [Related]
20. Sceletium tortuosum may delay chronic disease progression via alkaloid-dependent antioxidant or anti-inflammatory action.
Bennett AC; Van Camp A; López V; Smith C
J Physiol Biochem; 2018 Nov; 74(4):539-547. PubMed ID: 29520661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
